Myriad Genetics, Inc. (MYGN) Stock

Myriad Genetics, Inc. is a pioneering genetic testing and precision medicine company renowned for its development and global commercialization of advanced genetic tests. Operating both domestically and internationally, the company focuses on molecular diagnostic tests that span oncology, women's health, and mental health applications.

Among its flagship offerings, Myriad Genetics provides the MyRisk Hereditary Cancer Test, a leading DNA sequencing test designed to assess individuals' susceptibility to hereditary cancers. The BRACAnalysis CDx Germline Companion Diagnostic Test aids clinicians in determining appropriate therapies for patients with metastatic breast, ovarian, pancreatic, or prostate cancers possessing deleterious germline BRCA variants. Additionally, the MyChoice CDx Companion Diagnostic Test helps ascertain the homologous recombination deficiency status in ovarian cancer patients.

Myriad Genetics also delivers specialized RNA expression tests such as the Prolaris Prostate Cancer Prognostic Test and the EndoPredict Breast Cancer Prognostic Test. These tests provide crucial insights into the aggressiveness of prostate and breast cancers, respectively. The company's Precise Tumor solution contributes to precision oncology efforts, while the Prequel Prenatal Screen offers non-invasive prenatal screening for severe chromosomal disorders using maternal blood.

Further expanding its portfolio, Myriad Genetics offers the Foresight Carrier Screen, which assesses the risk of pasdsing on recessive genetic conditions to offspring. The GeneSight Psychotropic Mental Health Medication Test aids in selecting appropriate psychotropic medications for patients dealing with depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics collaborates strategically with industry leaders like Illumina, Inc. and Intermountain Precision Genomics to enhance its germline and somatic tumor testing services.

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics continues to innovate and set benchmarks in genetic testing and precision medicine, empowering healthcare providers and patients worldwide with critical genetic insights.